{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:53:43Z","timestamp":1793199223184,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.nmd.2021.08.004","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T02:40:20Z","timestamp":1635820820000},"page":"1013-1020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["The DMD gene and therapeutic approaches to restore dystrophin"],"prefix":"10.1016","volume":"31","author":[{"given":"Fernanda","family":"Fortunato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Farn\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8385-9870","authenticated-orcid":false,"given":"Alessandra","family":"Ferlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.08.004_bib0001","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/345315a0","article-title":"Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle","volume":"345","author":"Ervasti","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2021.08.004_bib0002","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41431-020-0643-7","article-title":"EMQN best practice guidelines for genetic testing in dystrophinopathies","volume":"28","author":"Fratter","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.nmd.2021.08.004_bib0003","first-page":"14","article-title":"Dystrophic Cardiomyopathy: complex pathobiological processes to generate clinical phenotype","volume":"4","author":"Tsuda","year":"2017","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.nmd.2021.08.004_bib0004","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/dmcn.12922","article-title":"Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations","volume":"58","author":"Ricotti","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2021.08.004_bib0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/genes11080837","article-title":"Therapeutic strategies for Duchenne muscular dystrophy: an update","volume":"11","author":"Sun","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.nmd.2021.08.004_bib0006","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","article-title":"Pharmacological advances for treatment in Duchenne muscular dystrophy","volume":"34","author":"Guiraud","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.nmd.2021.08.004_bib0007","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/humu.24191","article-title":"A single NGS-based assay covering the entire genomic sequence of the DMD gene facilitates diagnostic and newborn screening confirmatory testing","volume":"42","author":"Nallamilli","year":"2021","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nmd.2021.08.004_bib0008","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.08.004_bib0009","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/humu.20976","article-title":"Genotype-phenotype analysis in 2405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase","volume":"30","author":"Tuffery-Giraud","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nmd.2021.08.004_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fgene.2020.00131","article-title":"The genetic landscape of dystrophin mutations in Italy: a nationwide study","volume":"11","author":"Neri","year":"2020","journal-title":"Front Genet"},{"key":"10.1016\/j.nmd.2021.08.004_bib0011","doi-asserted-by":"crossref","first-page":"12575","DOI":"10.1038\/s41598-017-12981-5","article-title":"Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy","volume":"7","author":"Doorenweerd","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2021.08.004_bib0012","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nmd.2021.08.004_bib0013","first-page":"43","article-title":"Read-through approach for stop mutations in Duchenne muscular dystrophy. an update","volume":"40","author":"Politano","year":"2021","journal-title":"Acta Myol"},{"key":"10.1016\/j.nmd.2021.08.004_bib0014","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2217\/cer-2020-0095","article-title":"PTC124-GD-007-DMD study group; ACT DMD study group; clinical evaluator training groups. meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy","volume":"9","author":"Campbell","year":"2020","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.nmd.2021.08.004_bib0015","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/cer-2019-0086","article-title":"Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE registry","volume":"8","author":"Muntoni","year":"2019","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.nmd.2021.08.004_bib0016","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/cer-2019-0171","article-title":"STRIDE; CINRG Duchenne natural history investigators. safety and effectiveness of ataluren: comparison of results from the STRIDE registry and CINRG DMD natural history study","volume":"9","author":"Mercuri","year":"2020","journal-title":"J Comp Eff Res."},{"key":"10.1016\/j.nmd.2021.08.004_bib0017","unstructured":"European Medicines Agency. Translarna. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/translarna [(Accessed on 19 June 2021)]"},{"key":"10.1016\/j.nmd.2021.08.004_bib0018","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nmd.2021.08.004_bib0019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1126\/science.aba4515","article-title":"RNA-targeted drugs for neuromuscular diseases","volume":"371","author":"Ferlini","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.nmd.2021.08.004_bib0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nmd.2020.08.285","article-title":"Casimersen treatment in eligible patients with Duchenne muscular dystrophy: safety, tolerability, and pharmacokinetics over 144 weeks of treatment","volume":"30","author":"Kuntz","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.004_bib0021","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"SKIP-NMD study group. increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.08.004_bib0022","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in japanese Duchenne muscular dystrophy patients: a phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2021.08.004_bib0023","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15252\/emmm.201607199","article-title":"Delivery is key: lessons learnt from developing splice-switching antisense therapies","volume":"9","author":"Godfrey","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.nmd.2021.08.004_bib0024","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/978-1-4939-8651-4_24","article-title":"Use of tricyclo-DNA antisense oligonucleotides for exon skipping","volume":"1828","author":"Relizani","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.nmd.2021.08.004_bib0025","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.nmd.2021.08.004_bib0026","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.nmd.2018.06.009","article-title":"Personalized gene and cell therapy for Duchenne muscular dystrophy","volume":"28","author":"Barth\u00e9l\u00e9my","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.08.004_bib0027","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2021.08.004_bib0028","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.jip.2011.05.008","article-title":"Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases","volume":"107","author":"Galibert","year":"2011","journal-title":"J Invertebr Pathol"},{"key":"10.1016\/j.nmd.2021.08.004_bib0029","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2021.02.014","article-title":"Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec","volume":"21","author":"Day","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.nmd.2021.08.004_bib0030","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1517\/21678707.2015.1088780","article-title":"Gene therapy for Duchenne muscular dystrophy","volume":"3","author":"Ramos","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.nmd.2021.08.004_bib0031","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of In Vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2021.08.004_bib0032","unstructured":"Solid Biosciences (US). Reports efficacy and safety data from the ongoing IGNITE DMD clinical trial and resumption of patient dosing in the 2E14 vg\/kg cohort (Accessed on 19 June 2021)] https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-reports-efficacy-and-safety-data-from-the-ongoing-ignite-DMD-clinical-trial-and-resumption-of-patient-dosing-in-the-2e14-vg-kg-cohort"},{"key":"10.1016\/j.nmd.2021.08.004_bib0033","unstructured":"Sarepta Therapeutics\u2019 (US). Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, demonstrates robust expression and consistent safety profile using sarepta's commercial process material [(Accessed on 19 June 2021)] https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-investigational-gene-therapy-treatment"},{"key":"10.1016\/j.nmd.2021.08.004_bib0034","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2021.08.004_bib0035","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.nmd.2021.08.004_bib0036","doi-asserted-by":"crossref","first-page":"eaan8081","DOI":"10.1126\/scitranslmed.aan8081","article-title":"Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy","volume":"9","author":"Amoasii","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nmd.2021.08.004_bib0037","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00439-019-02028-2","article-title":"Therapeutic application of the CRISPR system: current issues and new prospects","volume":"138","author":"Lee","year":"2019","journal-title":"Hum Genet"},{"key":"10.1016\/j.nmd.2021.08.004_bib0038","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2174\/1381612824666180110151318","article-title":"Nanodiagnostics and nanodelivery applications in genetic alterations","volume":"24","author":"Falzarano","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nmd.2021.08.004_bib0039","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fgene.2018.00114","article-title":"Combined therapies for Duchenne muscular dystrophy to optimize treatment efficacy","volume":"9","author":"Cordova","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.nmd.2021.08.004_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246507","article-title":"Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice","volume":"16","author":"Ziemba","year":"2021","journal-title":"PLoS One"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621006088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621006088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:12:01Z","timestamp":1760775121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621006088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0960896621006088"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.08.004","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The DMD gene and therapeutic approaches to restore dystrophin","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}